Abstract
Background Georgia timely implemented effective response measures, with testing, contact tracing and isolation being the main pillar of the national response, achieving the lowest cumulative incidence of SARS-CoV-2 in the European region.
Methods We conducted a survey to estimate SARS-CoV-2 IgG antibody seroprevalence among adult residents of capital city of Tbilisi (adult population: 859,328). Participants were recruited through respondent driven sampling during May 18-27, 2020. Blood specimens were tested for SARS-CoV-2 IgG antibodies using commercially available lateral flow immunoassay (COVID-19 IgG/IgM Rapid Test Cassette, Zhejiang Orient Gene Biotech). Crude seroprevalence was weighted by population characteristics (age, sex, district of Tbilisi) and further adjusted for test accuracy.
Results Among 1,068 adults recruited 963 (90.2%) were between 18 and 64 years-old, 682 (63.9%) women. 176 (16.5%) reported symptoms indicative of SARS-CoV-2 infection occurring in previous three months. Nine persons tested positive for IgG: crude seroprevalence: 0.84%, (95% CI: 0.33%-1.59%), weighted seroprevalence: 0.94% (95% CI: 0.37%-1.95%), weighted and adjusted for test accuracy: 1.02% (95% CI: 0.38%-2.18%). The seroprevalence estimates translate into 7,200 to 8,800 infections among adult residents of Tbilisi, which is at least 20 times higher than the number of confirmed cases.
Conclusions Low seroprevalence confirms that Georgia successfully contained spread of SARS-CoV-2 during the first wave of pandemic. Findings also suggest that undocumented cases due to asymptomatic or very mild disease account for majority of infections. Given that asymptomatic persons can potentially spread the virus, test and isolate approach should be further expanded to control the epidemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study was approved by the Institutional Review Board of the Infectious Diseases, AIDS and Clinical Immunology Research Center (OHRP #: IRB00006106).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data availability is restricted in accordance with national laws and regulations. Data are available from the Infectious Diseases, AIDS and Clinical Immunology Research Center for qualifying researchers. Data requests can be made at aids@aidscenter.ge.